London Company of Virginia’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.27M Hold
37,453
0.01% 122
2025
Q4
$2.02M Sell
37,453
-787
-2% -$37.9K 0.01% 134
2025
Q3
$1.72M Sell
38,240
-7,506
-16% -$351K 0.01% 134
2025
Q2
$2.12M Hold
45,746
0.01% 127
2025
Q1
$2.79M Sell
45,746
-1,915
-4% -$112K 0.02% 128
2024
Q4
$2.7M Sell
47,661
-3,545
-7% -$198K 0.01% 130
2024
Q3
$2.65M Sell
51,206
-21,886
-30% -$1.03M 0.01% 129
2024
Q2
$3.04M Sell
73,092
-10,948
-13% -$490K 0.02% 130
2024
Q1
$4.56M Buy
84,040
+3,564
+4% +$182K 0.02% 127
2023
Q4
$4.13M Sell
80,476
-3,776
-4% -$198K 0.02% 125
2023
Q3
$4.89M Sell
84,252
-21,660
-20% -$1.33M 0.03% 122
2023
Q2
$6.77M Sell
105,912
-587
-0.6% -$39.4K 0.04% 113
2023
Q1
$7.38M Sell
106,499
-5,897
-5% -$416K 0.04% 113
2022
Q4
$8.09M Hold
112,396
0.05% 113
2022
Q3
$7.99M Sell
112,396
-3,597
-3% -$261K 0.05% 112
2022
Q2
$8.93M Sell
115,993
-1,484
-1% -$113K 0.05% 113
2022
Q1
$8.58M Sell
117,477
-162
-0.1% -$10.9K 0.05% 113
2021
Q4
$7.33M Sell
117,639
-82,954
-41% -$4.87M 0.04% 112
2021
Q3
$11.9M Sell
200,593
-492,593
-71% -$32.4M 0.07% 104
2021
Q2
$46.3M Buy
693,186
+7,578
+1% +$494K 0.25% 79
2021
Q1
$43.3M Buy
685,608
+5,305
+0.8% +$330K 0.25% 79
2020
Q4
$42.2M Buy
680,303
+5,414
+0.8% +$333K 0.26% 76
2020
Q3
$40.7M Sell
674,889
-6,788
-1% -$409K 0.29% 73
2020
Q2
$40.1M Buy
681,677
+3,291
+0.5% +$197K 0.31% 70
2020
Q1
$37.8M Buy
678,386
+4,023
+0.6% +$246K 0.36% 70
2019
Q4
$43.3M Sell
674,363
-20,413
-3% -$1.17M 0.33% 77
2019
Q3
$35.2M Sell
694,776
-30,733
-4% -$1.44M 0.29% 77
2019
Q2
$32.9M Sell
725,509
-155,407
-18% -$7.24M 0.28% 81
2019
Q1
$42M Buy
880,916
+6,352
+0.7% +$316K 0.36% 74
2018
Q4
$45.5M Sell
874,564
-47,891
-5% -$2.57M 0.43% 63
2018
Q3
$57.3M Sell
922,455
-31,837
-3% -$1.89M 0.45% 63
2018
Q2
$52.8M Sell
954,292
-45,315
-5% -$2.45M 0.43% 65
2018
Q1
$63.2M Sell
999,607
-1,944
-0.2% -$125K 0.51% 59
2017
Q4
$61.4M Sell
1,001,551
-18,925
-2% -$1.18M 0.44% 63
2017
Q3
$65M Sell
1,020,476
-40,707
-4% -$2.38M 0.47% 64
2017
Q2
$59.1M Sell
1,061,183
-64,780
-6% -$3.53M 0.4% 73
2017
Q1
$61.2M Sell
1,125,963
-33,109
-3% -$1.82M 0.4% 73
2016
Q4
$67.7M Sell
1,159,072
-90,418
-7% -$4.94M 0.47% 70
2016
Q3
$67.4M Buy
1,249,490
+36,124
+3% +$2.32M 0.5% 71
2016
Q2
$89.2M Sell
1,213,366
-9,748
-0.8% -$689K 0.69% 61
2016
Q1
$78.1M Sell
1,223,114
-2,388,893
-66% -$151M 0.64% 60
2015
Q4
$248M Buy
3,612,007
+479,003
+15% +$31.7M 2.15% 11
2015
Q3
$185M Buy
3,133,004
+115,802
+4% +$7.35M 1.72% 17
2015
Q2
$201M Buy
3,017,202
+398,849
+15% +$26.3M 1.74% 16
2015
Q1
$169M Buy
2,618,353
+301,806
+13% +$18.9M 1.55% 23
2014
Q4
$137M Buy
2,316,547
+222,344
+11% +$12.5M 1.43% 24
2014
Q3
$107M Buy
2,094,203
+51,360
+3% +$2.57M 1.2% 32
2014
Q2
$99.1M Buy
2,042,843
+122,950
+6% +$6.06M 1.08% 36
2014
Q1
$99.7M Sell
1,919,893
-285,982
-13% -$15.2M 1.12% 34
2013
Q4
$117M Buy
2,205,875
+321,632
+17% +$16.4M 1.34% 25
2013
Q3
$87.2M Buy
1,884,243
+111,750
+6% +$4.91M 1.19% 29
2013
Q2
$79.2M Buy
+1,772,493
New +$77M 1.15% 29

Other funds holding BMY

London Company of Virginia's BMY Position: Q1 2026 in Review

London Company of Virginia held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 37,453 shares worth $2.27M. The position accounts for 0.01% of the portfolio, ranked #122.

London Company of Virginia first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $248M in Q4 2015. 2,528 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • London Company of Virginia held 37,453 shares of Bristol-Myers Squibb worth $2.27M as of Q1 2026.
  • London Company of Virginia left its Bristol-Myers Squibb share count unchanged in Q1 2026.
  • Bristol-Myers Squibb made up 0.01% of London Company of Virginia's portfolio in Q1 2026, its #122 holding.
  • London Company of Virginia first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • London Company of Virginia's Bristol-Myers Squibb position peaked at $248M in Q4 2015.
  • 2,528 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on London Company of Virginia's 13F filing for Q1 2026, filed 15 May 2026.